respiratory
Lung cancer

SABR the treatment of choice for inoperable stage 1 NSCLC


Stereotactic ablative radiotherapy (SABR) should be the treatment of choice for patients with inoperable peripherally located stage 1 non-small cell lung cancer (NSCLC), say the Australian authors of a phase 3 trial published in Lancet Oncology. The randomised CHISEL trial conducted across 14 hospitals in Australia and New Zealand randomly assigned 101 patients with peripherally ...

Already a member?

Enter your email to keep reading.


OR